Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04635735 · ADVERSE EVENTS

Adverse events

Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma · Source last updated 2023-03-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame
up to a year
Other-event reporting threshold
5%
Participants affected / participants at risk, as reported
Safety groupSerious eventsOther eventsDeaths
Ipilimumab After Stem Cell Transplantation

The patient will be admitted to a single room on the Adult Transplantation Service and allogeneic CD34-selected PBSC or marrow transplantation performed as per MSKCC adult BMT guidelines. Patients will be evaluated at approximately day 100 (±2 weeks) after allo-HSCT. Ipilimumab: Ipilimumab 3 mg/kg every 3 weeks for 4 doses.

0 / 30 / 31 / 3

Group identifiers: EG000: Ipilimumab After Stem Cell Transplantation

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

    Other reported adverse events

    Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

      Complete source fields
      event Groups
      1. deaths Num Affected
        1
        deaths Num At Risk
        3
        description
        The patient will be admitted to a single room on the Adult Transplantation Service and allogeneic CD34-selected PBSC or marrow transplantation performed as per MSKCC adult BMT guidelines. Patients will be evaluated at approximately day 100 (±2 weeks) after allo-HSCT. Ipilimumab: Ipilimumab 3 mg/kg every 3 weeks for 4 doses.
        id
        EG000
        other Num Affected
        0
        other Num At Risk
        3
        serious Num Affected
        0
        serious Num At Risk
        3
        title
        Ipilimumab After Stem Cell Transplantation
      frequency Threshold
      5
      time Frame
      up to a year

      Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

      Preserved source evidence · Not medical advice